Looking forward, looking back.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 18464754.
- Also identified by DOI 10.1038/nbt0508-475.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Amgen's retrospective sortie into personalized Vectibix treatment poses some difficult questions for regulators concerning the oversight of companion diagnostics.
Medical subject headings
- Antibodies, Monoclonal
- Colorectal Neoplasms
- Decision Making
- Drug Approval
- Government Regulation
- United States Food and Drug Administration